



Attorney Docket No.: 4318.224-US

EST AMALGAM COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Serial No.: 09/902,188

Confirmation No: 7527

Filed: July 10, 2001

Group Art Unit: 1751

For: Amylase Variants

Examiner: To be assigned

**RESPONSE TO NOTICE TO FILE MISSING PARTS
AND TO NOTICE TO COMPLY WITH SEQUENCE RULES**

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Sequence Rules dated July 30, 2001, please amend the above-identified application as follows:

REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed in application no. 09/354191, filed July 15, 1999. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. This submission contains no new matter.


RECEIVED
OCT 09 2001
TC 1700

BEST AVAILABLE COPY

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 26, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

RECEIVED
OCT 03 2001
TC 1700